Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2001

View Archived Issues

CS-023 may have advantages over imipenem and meropenem according to preclinical data

Inhibition of PI3K enhances human sperm motility

AGI-1067 advances to phase IIb for treatment of restenosis and atherosclerosis

Targeted anti-Gram-positive oxazolidinone shows promise for resistant infections

Oritavancin phase III data, potential in anthrax infections discussed at ICAAC meeting

Adjunctive therapy with Actimmune in a serious invasive fungal infection

Vasomax amendment submitted in the U.K.

Pharmacia returns U.S. rights to Ambien to Sanofi-Synthelabo

Schering-Plough highlights promising therapeutics in development pipeline

Amylin anticipates filing NDA amendment for Symlin within the next six months

Salix seeks approval for rifaximin in travelers' diarrhea

Tularik presents SAR in a novel class of non-nucleoside anti-HCMV agents at ICAAC meeting

AstraZeneca and Lilly to collaborate on clinical trials with ZD-1839 and gemcitabine combination

Allopurinol reverses mechanoenergetic uncoupling in cardiomyopathy

Muscarinic agonist identified at Acadia reduces intraocular pressure in monkeys

New antiinflammatory steroids useful for asthma and various other conditions

N/OFQ receptor ligands useful as analgesics discovered by GSK

Boehringer Ingelheim patents compounds for asthma and other inflammatory disorders

Glycopeptide antibacterial agents designed by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...